Avapro
Home >> Avapro >> Drug Details
Irbesartan (INN) (pronounced /rbsrtn/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.
Clinical use
Indications
As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[2]
Combination with diuretic
Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including Irda, CoIrda, CoAprovel, Karvezide, Avalide and Avapro HCT.
No benefits seen for
A large randomized trial following 4100+ men and women with heart failure and normal ejection fraction (>=45%) over 4+ years found no improvement in study outcomes or survival with irbesartan as compared to placebo.[3]
Market
BMS annual sales approx $1.3bn. Sanofi-aventis annual sales approx $2.1bn. Patent expires in 2011.
References
- ^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes". N Engl J Med 345 (12): 85160. doi:10.1056/NEJMoa011303. PMID 11565517.
- ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- ^ Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A (December 2008). "Irbesartan in patients with heart failure and preserved ejection fraction". N. Engl. J. Med. 359 (23): 245667. doi:10.1056/NEJMoa0805450. PMID 19001508.
See also
Recent Avapro Forums View All 
Return to Top  Start a New Discussion About this Drug
This article is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License)
http://en.wikipedia.org/wiki/Avapro
This information has been independently compiled and is for educational purposes only. It is not intended to be a substitute for face to face medical advice from a qualified healthcare professional. Please remember that the content within this community is totally compiled by users of this site. Our website displays many pages which do not contain any medical information regarding the drug name stated. These pages are only provided for the purpose of opening community discussions about that drug by our users. For more details please see the Disclaimer. This data is Copyright © 2005-2009 PrescriptionDrug-Info.com and is protected under U.S. and International Copyright laws. All Rights Reserved.
drug_details.asp Last Updated September 21 2009
|
 Home Page
Post Your Story or Question
 Follow Us On Twitter
 Registered Community Experts
Topics Submitted 
Prescription Drug Forums
Top 200 Prescription Drugs
Drugs by Category
Recent FDA Approvals
November 2009 Health News
Advertising & Contact Details
About the Community
Medical Disclaimer
Terms of Use
Privacy Policy
Make Us Your Home Page
Bookmark this Page 
Recent Topics
Ward West 993
M 2 Pill What Is It
Nasal Spray
Progesterone
White Oval Pill M365
Watson Watson 393
Stalopam Plus
Lipoflavin
Daneuron
Oblong Peach Pill
Pacofen
Clonaz
Sulpride
White Pill 79
Zy
Cymbalata
Pill B M Fancy R
Prochlorp
Motrin 800 Mg
Pink W 50
Oxy 20
Benacal
Oxy Ir
Spirono
M B2 White Oval Pill
White Pill 276 Ig
Febrex
Feldene Flash
Etolodac
Pink Oblong Pill With B On It
|
Committed to Your Privacy 
